SCHEMBL4029036

SCHEMBL4029036

Oc1ccc(-c2n[nH]c3ccc(F)cc23)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 10/20 0.67
MAPK1 P28482 5/20 0.67
MAPK6 Q16659 5/20 0.67
MAPKAPK3 Q16644 4/20 0.67
MAPKAPK2 P49137 2/20 0.67
MAPKAPK5 Q8IW41 1/20 0.67
PDPK1 O15530 1/20 0.60
HSP90AB1 P08238 1/20 0.60
FGFR1 P11362 2/20 0.58
FGFR2 P21802 2/20 0.58
FGFR3 P22607 1/20 0.58
ITK Q08881 1/20 0.51
HTR2A P28223 1/20 0.50
MAP2K7 O14733 1/20 0.48
NTRK1 P04629 2/20 0.47
DHODH Q02127 2/20 0.47
MKNK1 Q9BUB5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14359839 0.90 MAP2K4 (0.62) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL5383296 0.83 MAPK1 (0.55) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL5377632 0.83 MAP2K4 (0.75) MAP2K4MAPK1MAPK6ITKHTR2A
SCHEMBL22801614 0.80 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL4025104 0.80 MAP2K4 (1.00) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL20379652 0.77 MAPT (0.66) MAP2K4MAPK1MAPK6ITKHTR2A
SCHEMBL2469031 0.77 AXL (0.55) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL1663652 0.77 FGFR1 (0.68) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL4332948 0.77 MAP2K4 (0.49) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL30415837 0.77 MAP2K4 (0.49) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
CN-101054364-A Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases WYETH CORP (US) 2007-10-17 CN disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
CN-1321984-C Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2007-06-20 CN disclosed
CN-1692102-A Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation WYETH CORP (US) 2005-11-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR MAP2K4 793/4885MAPK1 857/4885MAPK6 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.